Hemoglobin level significantly impacts the tumor cell survival fraction in humans after internal radiotherapy

EJNMMI Research

Volumn 2, Issue 1, 2012, Pages

  Walrand, Stephan ^a   Lhommel, Renaud ^a   Goffette, Pierre ^a   van den Eynde, Marc ^a   Pauwels, Stanislas ^a   Jamar, François ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Anemia; Dose response; Dosimetry; Hemoglobin; Internal radiotherapy; Liver SIRT

Indexed keywords

BLOOD CLOTTING FACTOR 6; FLUORODEOXYGLUCOSE F 18; HEMOGLOBIN; YTTRIUM 90;

ARTICLE; CANCER RADIOTHERAPY; CELL SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; LIVER METASTASIS; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION RESPONSE; RADIOSENSITIVITY; SELECTIVE INTERNAL RADIOTHERAPY; THREE DIMENSIONAL IMAGING; TUMOR CELL;

EID: 84873535536     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-2-20     Document Type: Article

References (47)

1. Caro JJ, Salas M, Ward A, Goss G: Anemia as an independent prognostic factor for survival in patients with cancer. A systemic quantitative review. Cancer 2001, 91:2214-2221.
2. Harrison LB, Shasha D, Homel P: Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology 2002, 63:11-18.
3. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D: Impact of tumour hypoxia and anemia on radiation therapy outcomes. Oncologist 2002, 7:492-508.
4. Nowrousian MR: Prevalence, pathophysiology, predictive factors, and prognostic significance of anemia in cancer chemotherapy. In Recombinant human erythropoietin (rhEPO) in clinical oncology. 2nd edition. Edited by Nowrousian MR. Wien, New York: Springer; 2002:63-100.
5. Van Belle SJ-P, Cocquyt V: Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003, 47:1-11.
6. Clarke H, Pallister CJ: The impact of anaemia on outcome in cancer. Clin Lab Haem 2005, 27:1-13.
7. Österborg A: Anaemia in patients with cancer: association to prognosis and prediction of response to erythropoietic agents. In Anaemia in Cancer. Edited by Bokemeyer C, Ludwig H. Edinburgh London New York: Elsevier; 2005.
8. Vaupel P, Mayer A: Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26(2):225-239.
9. Vaupel P, Mayer A, Höckel M: Relationship between hemoglobin levels and tumour oxygenation. In Recombinant human erythropoietin (rhEPO) in clinical oncology. Edited by Nowrousian MR. Wien, New York: Springer; 2008.
10. Höckel M, Vaupel P: Tumour hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93:266-276.
11. Semenza GL: Hypoxia, clonal selection, and the role of HIF-1 in tumour progression. Crit Rev Biochem Mol Biol 2000, 35:71-103.
12. Semenza GL: Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 2002, 41:79-83.
13. Semenza GL: HIF-1 and tumour progression: pathophysiology and therapeutics. Trends Mol Med 2002, 8(suppl 1):S62-S67.
14. Harris AL: Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
15. Leo C, Giaccia AJ, Denko NC: The hypoxic tumour microenvironment and gene expression. Semin Radiat Oncol 2004, 14:207-214.
16. Stabin MG: Fundamentals of nuclear medicine dosimetry. New York: Springer; 2008.
17. Beyzadeoglu M, Ozyigit G, Ebruli C: Radiobiology. In Basic radiation oncology. Edited by. New York: Springer; 2010.
18. McParland BJ: Biological effects of ionizing radiation. In Nuclear Medicine Radiation Dosimetry. Edited by. New York: Springer; 2010.
19. van der Poel HG, Antonini N, Hoefnagel CA, Horenblas S, Valdes Olmos RA: Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer. Urol Int 2006, 77(1):50-56.
20. Windsor PM: Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience: palliation and metastatic disease. Clin Oncol 2001, 13(3):219-227.
21. Wardman P: Chemical radiosensitizers for use in radiotherapy. Clin Oncol 2007, 19(6):397-417.
22. Ahn GO, Brown JM: Combinations of hypoxia-targeting compounds and radiationactivated prodrugs with ionizing radiation. In Multimodal concepts for integration of cytotoxic drugs and radiation therapy. Edited by. New York: Springer; 2006:67-91 [Brown MJ, Nieder C, Brady LW (Series Editors): Medical Radiology].
23. Janssen HL, Haustermans KM, Balm AJ, Begg AC: Hypoxia in head and neck cancer: how much, how important? Head Neck 2005, 27(7):622-638.
24. Hu K, Harrison LB: Impact of anemia in patients with head and neck cancer treated with radiation therapy. Curr Treat Options Oncol 2005, 6(1):31-45.
25. Ozsahin M, Azria D, Beer K, Mirimanoff RO, Zouhair A: External radiotherapy and anaemia treatment: state of the art. Swiss Med Wkly 2005, 135(1-2):4-10.
26. Horsman MR, van der Kogel AJ: Therapeutic approaches to tumour hypoxia. In Basic clinical radiobiology. Edited by Joiner M, van der Kogel A. London: MPG Books; 2009.
27. Lhommel R, Goffette P, Van den Eynde M, Jamar F, Pauwels S, Bilbao JI, Walrand S: Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur J Nucl Med Mol Imaging 2009, 36(10):1969.
28. Walrand S, Hesse S, Demonceau G, Pauwels S, Jamar F: Yttrium-90 labeled microspheres tracking during liver selective internal radiotherapy by bremsstrahlung pinhole SPECT: feasibility study and evaluation in an abdominal phantom. EJNMMI Res 2011, 1:32.
29. Werner MK, Brechtel K, Beyer T, Dittmann H, Pfannenberg C, Kupferschläger J: PET/CT for the assessment and quantification of 90Y biodistribution after selective internal radiotherapy (SIRT) of liver metastases. Eur J Nucl Med Mol Imaging 2010, 37(2):407-408.
30. Lhommel R, van Elmbt L, Goffette P, Van den Eynde M, Jamar F, Pauwels S, Walrand S: Feasibility of yttrium-90 TOF-PET based dosimetry in liver metastasis therapy using SIR-spheres. Eur J Nucl Med Mol Imaging 2010, 37(9):1654-1662.
31. van Elmbt L, Vandenberghe S, Walrand S, Pauwels S, Jamar F: Comparison of yttrium-90 quantitative imaging by TOF and non-TOF PET in a phantom of liver selective internal radiotherapy. Phys Med Biol 2011, 56(21):6759-6777.
32. Walrand S, Flux GD, Konijnenberg MW, Valkema R, Krenning EP, Lhommel R, Pauwels S, Jamar F: Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: (86)Y or (90)Y imaging? Eur J Nucl Med Mol Imaging 2011, 38(1 suppl 1):S57-S68.
33. Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, Porée P, Clément B, Raoul JL, Boucher E: Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med 2012, 53(2):255-263.
34. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A 3rd, Benson A, Espat J, Bilbao JI, Sharma RA, Thomas JP, Coldwell D: Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007, 68(1):13-23.
35. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, Pratt B, Husband J, Flower M, Ott R: Noninvasive monitoring of tumour metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumour response to fluorouracil. J Clin Oncol 1996, 14:700-708.
36. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, De Leyn P, Van Raemdonck D, De Wever W, Ectors N, Maes A, Mortelmans L: Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002, 13(3):361-368.
37. Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ, Connolly LP, Kunter G, Rodriguez-Galindo C, Wallis JW, Hurwitz CA, Schteingart DE: Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2006, 91(7):2665-2671.
38. Rades D, Kuhn H, Schultze J, Homann N, Brandenburg B, Schulte R, Krull A, Schild SE, Dunst J: Prognostic factors affecting locally recurrent rectal cancer and clinical significance of hemoglobin. Int J Radiat Oncol Biol Phys 2008, 70(4):1087-1093.
39. Fertil B, Malaise EP: Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumours: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 1985, 11(9):1699-1707.
40. Malaise EP, Fertil B, Chavaudra N, Guichard M: Distribution of radiation sensitivities for human tumour cells of specific histological types: comparison of in vitro to in vivo data. Rad Oncology Biol Phys 1986, 12:617-624.
41. Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, Iaccarino G, Benassi M, Ettorre GM, Maini CL: Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med 2010, 51(9):1377-1385.
42. Zheng XK, Chen LH, Yan X, Wang HM: Impact of prolonged fraction dose-delivery time modeling intensity-modulated radiation therapy on hepatocellular carcinoma cell killing. World J Gastroenterol 2005, 11(10):1452-1456.
43. Kato Y, Yashiro M, Fuyuhiro Y, Kashiwagi S, Matsuoka J, Hirakawa T, Noda S, Aomatsu N, Hasegawa T, Matsuzaki T, Sawada T, Ohira M, Hirakawa K: Effects of acute and chronic hypoxia on the radiosensitivity of gastric and esophageal cancer cells. Anticancer Res 2011, 31:3369-3376.
44. Carlson DJ, Keall PJ, Loo BW, Chen ZJ, Brown JM: Hypofractionation results in reduced tumour cell kill compared to conventional fractionation for tumours with regions of hypoxia. Int J Radiation Oncology Biol Phys 2011, 79(4):1188-1195.
45. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, Kvols LK, Krenning EP, Jamar F, Pauwels S: Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a doseeffect relationship. J Nucl Med 2005, 46(suppl 1):99S-106S.
46. Staab HJ, Anderer FA, Hornung A, Stumpf E, Fischer R: Doubling time of circulating CEA and its relation to survival of patients with recurrent colorectal cancer. Br J Cancer 1982, 46(5):773-781.
47. Fowler JF: The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989, 62:679-694.